Literature DB >> 11985510

Cellular immune responses against hepatitis C virus: the evidence base 2002.

S Ward1, G Lauer, R Isba, B Walker, P Klenerman.   

Abstract

Hepatitis C virus (HCV) is an RNA virus which is estimated to persistently infect about 170 million people worldwide. After acute infection, there is an initial period during which long-term outcome is decided. There is strong evidence that the cellular immune responses, involving both CD4+ and CD8+ T lymphocytes, are involved at this stage and it is their effectiveness which determines outcome. What is not understood is what determines their effectiveness. The most important component of this is likely to be some aspect of epitope selection, itself dictated by host MHC. Thus, to understand host immunity to HCV, we need to have a detailed understanding of the peptides involved in T lymphocyte responses. In this review, we discuss the peptide epitopes that have been identified so far, and their potential significance. We relate this to a scheme of host defence which may be useful for understanding natural and vaccine-induced immunity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11985510      PMCID: PMC1906407          DOI: 10.1046/j.1365-2249.2002.01840.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  79 in total

1.  Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.

Authors:  G Missale; R Bertoni; V Lamonaca; A Valli; M Massari; C Mori; M G Rumi; M Houghton; F Fiaccadori; C Ferrari
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection.

Authors:  K Hiroishi; H Kita; M Kojima; H Okamoto; T Moriyama; T Kaneko; T Ishikawa; S Ohnishi; T Aikawa; N Tanaka; Y Yazaki; K Mitamura; M Imawari
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

3.  Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS.

Authors:  P J Goulder; R E Phillips; R A Colbert; S McAdam; G Ogg; M A Nowak; P Giangrande; G Luzzi; B Morgan; A Edwards; A J McMichael; S Rowland-Jones
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

4.  Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection.

Authors:  D K Wong; D D Dudley; N H Afdhal; J Dienstag; C M Rice; L Wang; M Houghton; B D Walker; M J Koziel
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

5.  HLA B44-restricted cytotoxic T lymphocyte responses to the peptides of HCV nucleoprotein residues 81-100 in patients with chronic hepatitis C.

Authors:  H Kita; T Moriyama; T Kaneko; H Okamoto; K Hiroishi; S Ohnishi; M Imawari
Journal:  J Gastroenterol       Date:  1995-12       Impact factor: 7.527

6.  Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL.

Authors:  K Ando; K Hiroishi; T Kaneko; T Moriyama; Y Muto; N Kayagaki; H Yagita; K Okumura; M Imawari
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

7.  Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus.

Authors:  K M Chang; B Rehermann; J G McHutchison; C Pasquinelli; S Southwood; A Sette; F V Chisari
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

8.  Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons.

Authors:  M J Koziel; D K Wong; D Dudley; M Houghton; B D Walker
Journal:  J Infect Dis       Date:  1997-10       Impact factor: 5.226

9.  Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection.

Authors:  B Rehermann; K M Chang; J G McHutchison; R Kokka; M Houghton; F V Chisari
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

10.  Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients.

Authors:  B Rehermann; K M Chang; J McHutchinson; R Kokka; M Houghton; C M Rice; F V Chisari
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more
  47 in total

1.  Analysis of 'driver' and 'passenger' CD8+ T-cell responses against variable viruses.

Authors:  Andreas Zafiropoulos; Eleanor Barnes; Clive Piggott; Paul Klenerman
Journal:  Proc Biol Sci       Date:  2004-02-07       Impact factor: 5.349

2.  Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.

Authors:  Andrea L Cox; Timothy Mosbruger; Georg M Lauer; Drew Pardoll; David L Thomas; Stuart C Ray
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

3.  Flow cytometry assay of myeloid dendritic cells (mDCs) in peripheral blood during acute hepatitis C: possible pathogenetic mechanisms.

Authors:  Alessandro Perrella; Luigi Atripaldi; Pasquale Bellopede; Tommaso Patarino; Costanza Sbreglia; Giovanni Tarantino; Paolo Sorrentino; Paolo Conca; Luca Ruggiero; Oreste Perrella
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

Review 4.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

5.  Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model.

Authors:  Keisuke Ojiro; Xiaowang Qu; Hyosun Cho; Jang-June Park; Annelise Vuidepot; Nikolai Lissin; Peter E Molloy; Alan Bennett; Bent K Jakobsen; David E Kaplan; James L Riley; Kyong-Mi Chang
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

6.  Computational reconstruction of Bole1a, a representative synthetic hepatitis C virus subtype 1a genome.

Authors:  Supriya Munshaw; Justin R Bailey; Lin Liu; William O Osburn; Kelly P Burke; Andrea L Cox; Stuart C Ray
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

7.  Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection.

Authors:  Silvana Gaudieri; Andri Rauch; Lawrence P Park; Elizabeth Freitas; Susan Herrmann; Gary Jeffrey; Wendy Cheng; Katja Pfafferott; Kiloshni Naidoo; Russell Chapman; Manuel Battegay; Rainer Weber; Amalio Telenti; Hansjakob Furrer; Ian James; Michaela Lucas; Simon A Mallal
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

Review 8.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

9.  High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome.

Authors:  Carmen E Gómez; Beatriz Perdiguero; María Victoria Cepeda; Lidia Mingorance; Juan García-Arriaza; Andrea Vandermeeren; Carlos Óscar S Sorzano; Mariano Esteban
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

10.  Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection.

Authors:  Shuo Li; Stefan Floess; Alf Hamann; Silvana Gaudieri; Andrew Lucas; Margaret Hellard; Stuart Roberts; Geza Paukovic; Magdalena Plebanski; Bruce E Loveland; Campbell Aitken; Simon Barry; Louis Schofield; Eric J Gowans
Journal:  PLoS Pathog       Date:  2009-12-24       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.